Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study

Background: Many biological drugs have a rival version produced from different cell lines by other manufacturers; these drugs are referred to as biosimilars. By providing accurate information, encouraging patient and medical community acceptance, and advocating for their appropriate usage, pharmacists can play a crucial role in supporting the uptake of biosimilar medicines. Aim: This study aimed to assess pharmacists’ knowledge and attitudes toward biosimilar medicines in the Aseer region in Saudi Arabia. Methods: The study employed a descriptive, cross-sectional design using an anonymous online self-administered questionnaire. The questionnaire was developed by adapting a previously validated instrument and consisted of three sections: demographic data, knowledge about biosimilars, and attitudes toward biosimilars. Two non-probability sampling approaches, i.e., convenience and snowball sampling, were using for data collection. Results: A total of 298 pharmacists participated in the current study. Overall, a total of 135 (45.3%) demonstrated good knowledge of biosimilar medicines, while 163 (54.7%) exhibited poor knowledge. The median knowledge score among the study participants was 5 (5–6). Only 26.2% of pharmacists in the current study correctly identified that biosimilars were not generics and not interchangeable with reference biologics. More experienced pharmacists and those working in industry-related sectors demonstrated greater knowledge of biosimilars (p < 0.05). Pharmacists in the current study demonstrated generally favorable attitudes toward biosimilar medicines. Conclusions: The current study revealed knowledge gaps regarding biosimilar medicines among pharmacists. Targeted educational initiatives, continuing professional development opportunities, and enhanced curricular content could be implemented to address these gaps.